KR20070119678A - 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법 - Google Patents

지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법 Download PDF

Info

Publication number
KR20070119678A
KR20070119678A KR1020077023308A KR20077023308A KR20070119678A KR 20070119678 A KR20070119678 A KR 20070119678A KR 1020077023308 A KR1020077023308 A KR 1020077023308A KR 20077023308 A KR20077023308 A KR 20077023308A KR 20070119678 A KR20070119678 A KR 20070119678A
Authority
KR
South Korea
Prior art keywords
formulation
another embodiment
surface stabilizer
particle size
ziprasidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020077023308A
Other languages
English (en)
Korean (ko)
Inventor
제이민 찬드라칸트 샤
파랑 수레쉬 샤
돈 리네 와그너
피터 위스닉키
Original Assignee
화이자 프로덕츠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 프로덕츠 인코포레이티드 filed Critical 화이자 프로덕츠 인코포레이티드
Publication of KR20070119678A publication Critical patent/KR20070119678A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020077023308A 2005-04-13 2006-04-10 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법 Abandoned KR20070119678A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67112405P 2005-04-13 2005-04-13
US60/671,124 2005-04-13

Publications (1)

Publication Number Publication Date
KR20070119678A true KR20070119678A (ko) 2007-12-20

Family

ID=36602931

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077023308A Abandoned KR20070119678A (ko) 2005-04-13 2006-04-10 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법

Country Status (14)

Country Link
US (1) US20080193542A1 (cg-RX-API-DMAC7.html)
EP (1) EP1874268A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008538751A (cg-RX-API-DMAC7.html)
KR (1) KR20070119678A (cg-RX-API-DMAC7.html)
CN (1) CN101166514A (cg-RX-API-DMAC7.html)
AU (2) AU2006233345A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0609299A2 (cg-RX-API-DMAC7.html)
CA (1) CA2605153A1 (cg-RX-API-DMAC7.html)
IL (1) IL186131A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007012103A (cg-RX-API-DMAC7.html)
NZ (1) NZ561950A (cg-RX-API-DMAC7.html)
RU (1) RU2407529C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006109183A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708188B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230025062A (ko) * 2021-08-13 2023-02-21 단국대학교 천안캠퍼스 산학협력단 결정형 몬테루카스트를 포함하는 지속성 현탁 주사제 및 이의 제조방법

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1623703B1 (en) 1999-10-29 2011-10-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
HU230875B1 (hu) 2000-10-30 2018-11-29 Euro-Celtique S.A. Szabályozott hatóanyag-leadású hidrokodon készítmények
TW200526221A (en) * 2003-09-02 2005-08-16 Imran Ahmed Sustained release dosage forms of ziprasidone
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
HK1117060A1 (en) * 2005-06-20 2009-01-09 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
EP2175857B1 (en) * 2007-07-12 2013-09-11 Janssen R&D Ireland Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
RS60651B1 (sr) 2011-04-15 2020-09-30 Janssen Pharmaceutica Nv Nanosuspenzije leka osušene zamrzavanjem
CN104814926A (zh) * 2015-04-08 2015-08-05 中国药科大学 一种鲁拉西酮纳米混悬剂及其制备方法
MX2018003380A (es) * 2015-09-21 2018-08-16 Teva Pharmaceuticals Int Gmbh Formulaciones de olanzapina de liberacion sostenida.
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
CN109998991A (zh) * 2019-04-28 2019-07-12 中国药科大学 一种盐酸鲁拉西酮长效肌肉注射纳米混悬液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
EP1575616A2 (en) * 2002-10-25 2005-09-21 Pfizer Products Inc. Novel injectable depot formulations
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TW200526221A (en) * 2003-09-02 2005-08-16 Imran Ahmed Sustained release dosage forms of ziprasidone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230025062A (ko) * 2021-08-13 2023-02-21 단국대학교 천안캠퍼스 산학협력단 결정형 몬테루카스트를 포함하는 지속성 현탁 주사제 및 이의 제조방법

Also Published As

Publication number Publication date
RU2407529C2 (ru) 2010-12-27
NZ561950A (en) 2010-09-30
BRPI0609299A2 (pt) 2010-03-23
JP2008538751A (ja) 2008-11-06
AU2010201801A1 (en) 2010-05-27
EP1874268A1 (en) 2008-01-09
MX2007012103A (es) 2007-11-20
WO2006109183A1 (en) 2006-10-19
AU2006233345A1 (en) 2006-10-19
US20080193542A1 (en) 2008-08-14
RU2007137846A (ru) 2009-06-20
ZA200708188B (en) 2008-10-29
IL186131A0 (en) 2008-01-20
CN101166514A (zh) 2008-04-23
CA2605153A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
US20080305161A1 (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
AU2010201801A1 (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US11717481B2 (en) Reduction of flake-like aggregation in nanoparticulate active agent compositions
HU226070B1 (en) Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
WO2010138661A1 (en) Nanoparticulate anticancer compositions and methods for making the same
WO2009076620A1 (en) Nanoparticulate anidulafungin compositions and methods for making the same
EP1874267A1 (en) Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
HK1117740A (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
WO2025008726A1 (en) Stable paliperidone palmitate composition using thermal treatment
EP4595959A1 (en) Sterilized heterocyclidene-acetamide-derivative-containing suspension
HK40049829B (zh) 阿立哌唑前体药物组合物
HK1235663A1 (en) Reduction of flake-like aggregation in nanoparticulate meloxicam compositions

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20071011

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090828

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100728

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090828

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20101028

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20100728

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20110103

Appeal identifier: 2010101008258

Request date: 20101028

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20101129

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20101028

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20100302

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20110103

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20101207

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee